FIGURE 1.

ALKBH5 and FTO expression in ovarian cancer tissues and normal ovarian tissues. A, Relative expression of ALKBH5 and FTO in EOC tissues (n = 73) compared with normal tissues (n = 37). ALKBH5 and FTO mRNA expressions were examined by qPCR and normalized to GAPDH expression, and examined by Western blot which were normalized to β‐actin expression. ALKBH5 and FTO have higher expression in ovarian epithelial cancer tissues than normal ones (*P < .05). B, qRT‐PCR and Western blot analysis of ALKBH5 and FTO mRNA and protein expression in normal ovarian cells (IOSE), EOC cell (A2780, SKOV3, HO‐8910 and OVCAR‐3) and endometrial cancer cell line (Ishikawa). ALKBH5 and FTO have lower expression in ovarian cancer cell lines than normal one (*P < .05). Representative images and data based on three independent experiments. C, Small interfering RNA (siRNA) knocks down the expression of ALKBH5 and detects its interference efficiency separately. The interference sequence si‐ALKBH5 3# has the highest interference efficiency and is selected as the experimental interference sequence. D, Knockdown of ALKBH5 expression could reduce proliferation of A2780 and HO8910 ovarian cancer cells. E, Flow cytometry results show the apoptotic rate was higher in A2780 and HO8910 cells transfected with si‐ALKBH5 than those of controls